Ariad Pharmaceuticals, Inc. Announces Positive Opinion By The European Medicines Agency On The Continued Availability Of Iclusig In Patients With Leukaemias

Published: Nov 22, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) on the continued availability of Iclusig® (ponatinib) in the EU for use in patients in its authorized indications.

Help employers find you! Check out all the jobs and post your resume.

Back to news